How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?

Arthritis Research and Therapy

Volumn 11, Issue 5, 2009, Pages

  Kamen, Diane L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIMALARIAL AGENT; HYDROXYCHLOROQUINE; PNEUMOCOCCUS VACCINE; PREDNISONE; RITUXIMAB;

DRUG DOSE INCREASE; EDITORIAL; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HIGH RISK PATIENT; HUMAN; INFECTION; INFECTION RISK; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PNEUMOCOCCAL INFECTION; PROPHYLAXIS; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK REDUCTION; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; VACCINATION; COMMUNICABLE DISEASE; IMMUNOLOGY; INFECTION CONTROL; METHODOLOGY; NOTE; RISK FACTOR;

COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 75649103234     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2818     Document Type: Editorial

References (8)

1. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009, 11:R109. 10.1186/ar2764, 2745791, 19604357.
2. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejía JC, Aydintug AO, Chwalinska-Sadowska H, de Ramón E, Fernández-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR, . European Working Party on Systemic Lupus Erythematosus Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003, 82:299-308. 10.1097/01.md.0000091181.93122.55, 14530779, European Working Party on Systemic Lupus Erythematosus.
3. Goldblatt F, Chambers S, Rahman A, Isenberg DA. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 2009, 18:682-689. 10.1177/0961203308101019, 19502263.
4. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995, 22:1259-1264.
5. Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008, 67(Suppl 3):iii2-25. 10.1136/ard.2008.100834, 19022808.
6. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2009,
7. Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, Vila LM, Reveille JD. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007, 66:1168-1172. 10.1136/ard.2006.068676, 17389655.
8. Millet A, Decaux O, Perlat A, Grosbois B, Jego P. Systemic lupus erythematosus and vaccination. Eur J Intern Med 2009, 20:236-241. 10.1016/j.ejim.2008.07.017, 19393490.